Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT04753606
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT04753606
-
- Main results
- Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04753606. Randomized; quadruple masking; primary purpose treatment. Start 2021-02-18 (actual); primary completion 2021-05-24 (actual). Results posted on 2024-06-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
- Acronym
- ROSE
- Condition
- Dyslipidemias
- Condition
- High Cholesterol
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Obicetrapib
- Lead sponsor
- NewAmsterdam Pharma
Record details
- Record id
cardio:ct-nct04753606- Content hash
40f38d2d63f84e754633607c7324036f2a9f82319c561df11fc1d4999b7b3517